State-of-The-Art management of dysplastic Barrett's esophagus

Kornpong Vantanasiri, Prasad G. Iyer

Research output: Contribution to journalReview articlepeer-review


Endoscopic eradication therapy (EET) has become a standard of care for treatment of dysplastic Barrett's esophagus (BE) and early Barrett's neoplasia. EET mainly consists of removal of any visible lesions via endoscopic resection and eradication of all remaining Barrett's mucosa using endoscopic ablation. Endoscopic mucosal resection and endoscopic submucosal dissection are the two available resection techniques. After complete resection of all visible lesions, it is crucial to perform endoscopic ablation to ensure complete eradication of the remaining Barrett's segment. Endoscopic ablation can be done either with thermal techniques, including radiofrequency ablation and argon plasma coagulation, or cryotherapy techniques. The primary end point of EET is achieving complete remission of intestinal metaplasia (CRIM) to decrease the risk of dysplastic recurrence after successful EET. After CRIM is achieved, a standardized endoscopic surveillance protocol needs to be implemented for early detection of BE recurrence.

Original languageEnglish (US)
Article numbergoac068
JournalGastroenterology Report
StatePublished - 2022


  • Barrett's esophagus
  • endoscopic eradication therapy
  • endoscopic mucosal resection
  • endoscopic submucosal dissection
  • esophageal adenocarcinoma

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'State-of-The-Art management of dysplastic Barrett's esophagus'. Together they form a unique fingerprint.

Cite this